Feline Immunodeficiency Virus Infection

Feline Immunodeficiency Virus (FIV) is a lentivirus in the family Retroviridae that selectively infects and depletes CD4+ T-lymphocytes, progressively impairing the cat's cell-mediated immune system in a manner broadly analogous to HIV infection in humans. It is one of the most common infectious diseases in domestic cats worldwide, with seroprevalence estimated at 1–14% in healthy cats and higher rates in ill or high-risk populations. The virus integrates its RNA genome (via reverse transcriptase) permanently into the host's DNA, making infection lifelong and incurable. Despite this, many infected cats can live for years with a normal or near-normal quality of life before advancing to the immunodeficiency stage.

Causative Agent: FIV is a single-stranded, enveloped RNA lentivirus. Multiple subtypes (clades A through E, plus F in some regions) have been identified globally, with geographic variation in prevalence of individual clades.

Transmission: The primary mode of transmission is through deep bite wounds, as the virus is shed in high concentrations in saliva. Casual contact (shared food bowls, grooming) carries extremely low transmission risk. Vertical transmission from queen to kittens can occur (in utero, peripartum, or via milk), though maternally acquired antibodies can cause false-positive test results in kittens under 6 months. Sexual transmission is possible but considered minor compared to biting.

Pathological Mechanism:

1. ·Initial Infection: FIV binds to CD134 (OX40) as its primary receptor, with CXCR4 as a co-receptor, on the surface of activated CD4+ T-lymphocytes and other immune cells (macrophages, dendritic cells, astrocytes).
2. ·Reverse Transcription and Integration: The viral RNA is reverse-transcribed into proviral DNA, which integrates permanently into the host genome, establishing a lifelong latent reservoir.
3. ·CD4+ T-cell Depletion: Ongoing viral replication leads to progressive loss of CD4+ helper T-cells through direct cytopathic effects, immune-mediated killing, and impaired lymphocyte production. The CD4+:CD8+ ratio inverts over time.
4. ·Immune Dysregulation: Concurrent CD8+ T-cell expansion, B-cell dysfunction, and chronic immune activation lead to hypergammaglobulinemia, neutrophil dysfunction, and ultimately profound immunosuppression.
5. ·Opportunistic Disease: The failing immune system cannot control secondary pathogens or suppress neoplastic transformation, leading to the clinical AIDS-like syndrome.

Clinical Suspicion: FIV should be suspected in any cat with chronic or recurrent infections, oral disease, unexplained weight loss, or known exposure risk (outdoor, male, free-roaming cats with bite wound history).

Point-of-Care Serology (ELISA / Rapid Test):

• ·The standard first-line test detects antibodies against FIV in whole blood, serum, or plasma.
• ·Positive results indicate exposure and, in cats >6 months of age with no prior vaccination history, are highly specific for infection.
• ·Kittens under 6 months: Maternal antibodies may cause false positives; re-test after 6 months of age.
• ·Recently infected cats: Antibodies may not appear until 8–12 weeks post-infection; a negative result does not exclude acute infection.
• ·FIV-vaccinated cats: The earlier FIV vaccine (now discontinued in many countries) caused antibody-positive results indistinguishable from natural infection; microchip documentation of vaccination history is essential.

Western Blot / Immunofluorescence Assay (IFA): Used as confirmatory tests when ELISA results are ambiguous.

PCR (Polymerase Chain Reaction):

• ·Detects proviral DNA; useful in kittens (before maternal antibodies clear), vaccinated cats, or inconclusive serology cases.
• ·Sensitivity varies by clade; false negatives possible with highly divergent strains.

Laboratory Findings (Hematology and Chemistry):

Imaging:

• ·Thoracic and abdominal radiographs or ultrasound may reveal lymphadenopathy, hepatosplenomegaly, or evidence of concurrent infections/neoplasia.
• ·Neurological FIV may warrant MRI/CT of the brain.

CD4+ T-cell Count: Flow cytometry to quantify CD4+ lymphocytes provides prognostic information but is not routinely available in all practices.

There is no curative treatment for FIV; management focuses on maintaining quality of life, managing secondary infections, and slowing disease progression.

Antiviral Therapy:

• ·Zidovudine (AZT/Azidothymidine): The most studied antiviral in FIV-positive cats. It reduces viral load, may improve clinical signs (especially neurological and oral disease), and can temporarily improve CD4+ counts. Dose: approximately 5–10 mg/kg PO or SC q12h. Adverse effects include hemolytic anemia; regular CBC monitoring (every 2–4 weeks initially) is mandatory.
• ·Feline Interferon-ω (IFN-ω; Virbagen Omega): Available in Europe and Japan. Has immunomodulatory and antiviral properties; may reduce clinical severity and viral load. Administered SC at 1 MU/kg daily for 5 days, repeated in cycles.
• ·Human Recombinant Interferon-α (rHuIFN-α): Used at low oral doses (30 IU/cat q24h) as an immunomodulator; evidence is limited but some benefit in managing chronic stomatitis and secondary disease.
• ·PMEA / Adefovir and other nucleoside analogues: Investigated experimentally; not in routine clinical use.

Management of Secondary and Opportunistic Infections:

• ·Antimicrobials selected based on culture and sensitivity for bacterial infections.
• ·Antifungals (itraconazole, fluconazole) for fungal opportunists.
• ·Antiparasitic drugs for concurrent protozoal infections (e.g., Toxoplasma, Cryptosporidium).
• ·Aggressive dental and oral care for stomatitis (professional scaling, extraction of affected teeth often significantly improves quality of life).

Immunosuppressive Drugs (Cautious Use):

• ·Corticosteroids and cyclosporine may be needed for immune-mediated complications (e.g., immune-mediated hemolytic anemia, lymphoplasmacytic stomatitis) but carry risk of further immunosuppression.

Nutritional Support:

• ·High-quality, balanced diet; assisted feeding (esophagostomy or nasogastric tube) if anorexic.
• ·Avoid raw food diets in immunocompromised FIV-positive cats due to risk of foodborne pathogens.

Supportive Care:

• ·Regular veterinary monitoring (every 6 months minimum): full CBC, serum chemistry, urinalysis, body weight.
• ·Anemia management: iron supplementation, erythropoietin-stimulating agents (with caution).
• ·Thrombocytopenia: treated based on severity and cause.
• ·Keep cats strictly indoors to reduce exposure to pathogens and prevent transmission to other cats.

Neoplasia:

• ·Lymphoma and other FIV-associated tumors treated with standard chemotherapy protocols where appropriate, though response may be poorer than in FIV-negative cats.

The prognosis of FIV infection is highly variable and stage-dependent. FIV infection alone does not equate to a death sentence; the clinical course ranges from asymptomatic carrier for the cat's natural lifespan to rapid progression to AIDS-like disease.

Key Prognostic Points:

• ·Asymptomatic carriers in the chronic phase can have a near-normal lifespan, sometimes surviving 10+ years without developing AIDS-stage disease. Studies suggest that a significant proportion of FIV-positive cats die from causes unrelated to FIV.
• ·Once AIDS-like immunodeficiency develops, prognosis becomes more guarded. Severe opportunistic infections, persistent weight loss, neurological disease, and concurrent neoplasia significantly worsen outcomes.
• ·CD4+ T-cell count is the most useful prognostic marker: counts below 200 cells/µL are associated with markedly increased risk of opportunistic infection and shorter survival.
• ·Concurrent infections (FeLV co-infection, Mycoplasma haemofelis, Toxoplasma gondii) substantially worsen prognosis.
• ·Oral disease responds well to aggressive dental management and does not independently predict poor long-term survival.
• ·FIV-associated lymphoma carries a poor to grave prognosis, with median survival typically measured in months with or without chemotherapy.

General Statement on Survival: While specific peer-reviewed survival statistics were not available in the references cited above, the general veterinary consensus is that many FIV-positive cats can live for 2–5+ years after diagnosis in the asymptomatic phase, and overall median survival post-diagnosis (all stages combined) is difficult to define precisely but is substantially longer than initially feared when the disease was first characterized. Quality of life and lifespan are highly dependent on veterinary management, indoor housing, and control of secondary disease.

Vaccination:

• ·An FIV vaccine (Fel-O-Vax FIV, Fort Dodge) was previously available in the United States, Australia, and a few other countries but has been discontinued in most markets. Its use created significant diagnostic confusion since vaccinated cats tested antibody-positive on standard ELISA tests.
• ·No universally available, widely recommended FIV vaccine currently exists in most countries. Vaccination status should be documented and microchipped cats' records updated accordingly.

Husbandry and Lifestyle Management:

• ·Indoor housing: The single most effective preventive measure. Cats kept strictly indoors with no contact with FIV-positive cats have extremely low acquisition risk.
• ·Neutering/Spaying: Castration of male cats dramatically reduces fighting and territorial aggression, the primary mechanism of virus transmission via bite wounds.
• ·Avoid introduction of unknown-status cats: All new cats entering a multi-cat household should be tested for FIV (and FeLV) before integration.
• ·Separate FIV-positive cats: In multi-cat households, FIV-positive cats that are peaceful and non-aggressive can safely coexist with FIV-negative cats due to the low risk of casual transmission; however, any cat that bites should be separated.
• ·Wound care: Any bite wound in a cat with unknown exposure history warrants prompt veterinary evaluation and FIV testing.
• ·Breeding programs: Queens and toms used for breeding should be tested and confirmed FIV-negative; infected queens should not be bred to prevent vertical transmission.

Public and Owner Education:

• ·Owners of FIV-positive cats should be educated that the virus is not transmissible to humans or non-feline pets.
• ·Regular biannual veterinary wellness visits for FIV-positive cats allow early detection of secondary disease and timely intervention.